PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31563592-0	2019	Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3beta/beta-catenin signaling pathway in the SH-SY5Y cell line.	Famotidine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	79-88	
31563592-7	2019	In this study, we aimed to investigate the effects of famotidine on the Akt/GSK-3beta/beta-catenin signaling pathway on SH-SY5Y neuroblastoma cells in the presence of MK-801.	Famotidine	54-64	glycogen synthase kinase 3 beta	Homo sapiens	76-85	
31563592-11	2019	Pre-treatments with famotidine, olanzapine, and SB 415286 prevented MK-801 induced cell death via inhibitory effects on the MK-801 induced GSK-3beta activity.	Famotidine	20-30	glycogen synthase kinase 3 beta	Homo sapiens	139-148	
31563592-12	2019	Overall, the present results suggest that famotidine has a neuroprotective effect against MK-801 via modulation of the Akt/GSK-3beta/beta-catenin signaling pathway, an important mechanism in schizophrenia neurobiology.	Famotidine	42-52	glycogen synthase kinase 3 beta	Homo sapiens	123-132	
31563592-6	2019	A recent study based on computerized drug modeling software (docking) indicated that famotidine might inhibit the GSK3beta activity due to its chemical structure independent from histaminergic receptors.	Famotidine	85-95	glycogen synthase kinase 3 beta	Homo sapiens	114-122	
22512725-0	2013	Famotidine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.	Famotidine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	20-50	
22512725-1	2013	Famotidine was investigated as an inhibitor of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain the molecular mechanism of its hypoglycemic side effects.	Famotidine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	47-77	
22512725-1	2013	Famotidine was investigated as an inhibitor of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain the molecular mechanism of its hypoglycemic side effects.	Famotidine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	79-88	
22512725-3	2013	Docking studies showed how famotidine is optimally fit within the binding pocket of GSK-3beta via numerous attractive interactions with some specific amino acids.	Famotidine	27-37	glycogen synthase kinase 3 beta	Homo sapiens	84-93	
22512725-4	2013	Experimentally, famotidine could inhibit GSK-3beta (IC50 = 1.44 muM) and increased significantly liver glycogen spares in fasting animal models.	Famotidine	16-26	glycogen synthase kinase 3 beta	Homo sapiens	41-50